KPV, PepT1 and Colitis-Associated Tumorigenesis in Mice

This study used PepT1-overexpressing and PepT1-deficient mice to examine transporter involvement in colitis-associated tumorigenesis and KPV-related effects.

Study design

Researchers induced colitis-associated cancer with AOM/DSS, compared tumour and inflammatory measurements across mouse genotypes, examined human biopsy expression, and administered KPV to mice with or without PepT1.

What the researchers reported

PepT1 overexpression was associated with greater tumour burden and inflammation, while deletion showed the opposite pattern. KPV was associated with reduced tumorigenesis in wild-type but not PepT1-deficient mice.

What this result does not establish

The intervention evidence came from a chemically induced mouse model. Human biopsy expression was observational and does not establish that KPV prevents or treats colorectal cancer in people.

This article summarizes one published study about KPV. It does not establish clinical efficacy, general safety, regulatory approval or suitability for human use. Findings should be interpreted within the model, methods and limitations of the original paper.